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Background: Each year approximately 3000 patients in the United Kingdom undergo surgery for esophagogastric
cancer. Jejunostomy feeding tubes, placed at the time of surgery for early postoperative nutrition, have been
shown to have a positive impact on clinical outcomes in the short term. Whether feeding out of hospital is of
benefit is unknown. Local experience has identified that between 15 and 20% of patients required ‘rescue’
jejunostomy feeding for nutritional problems and weight loss while at home. This weight loss and poor nutrition
may contribute to the detrimental effect on the overall quality of life (QoL) reported in these patients.
Methods/Design: This randomized pilot and feasibility study will provide preliminary information on the routine
use of jejunostomy feeding after hospital discharge in terms of clinical benefits and QoL. Sixty participants
undergoing esophagectomy or total gastrectomy will be randomized to receive either a planned program of six
weeks of home jejunostomy feeding after discharge from hospital (intervention) or treatment-as-usual (control). The
intention of this study is to inform a multi-centre randomized controlled trial. The primary outcome measures will
be recruitment and retention rates at six weeks and six months. Secondary outcome measures will include disease
specific and general QoL measures, nutritional parameters, total and oral nutritional intake, hospital readmission
rates, and estimates of healthcare costs. Up to 20 participants will also be enrolled in a qualitative sub-study that will
explore participants’ and carers’ experiences of home tube feeding.
The results will be disseminated by presentation at surgical, gastroenterological and dietetic meetings and
publication in appropriate peer review journals. A patient-friendly lay summary will be made available on the
University of Leicester and the University Hospitals of Leicester NHS Trust websites. The study has full ethical and
institutional approval and started recruitment in July 2012.
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Each year 13,500 patients in the United Kingdom are di-
agnosed with esophagogastric cancer [1]. Approximately
a quarter of these patients will undergo surgery, with an
ensuing median survival of around 2.5 years. Overall,
after surgery 30% of patients will be cured of their
cancer [2].
Nutritional support is considered important from diag-
nosis, through treatment, and in the palliative stages of
the disease. Feeding tubes (jejunostomy (JEJ)) inserted
into the small bowel during surgery allow early postop-
erative nutrition while patients are nil by mouth. JEJ are
recommended by international groups [3] as they have
been shown to have a positive impact on clinical outcomes
in short-term studies [4-6]. Despite this, the proportion of
patients having a feeding jejunostomy inserted varies
greatly between NHS centers across the country [7] and
the timing of discontinuing JEJ feeds is variable and not al-
ways related to the adequacy of oral nutritional intake [8].
The effect of supplementary JEJ feeds on oral intake has
not been prospectively assessed but it is routine for tube
feeds to be discontinued one to two weeks post-surgery in
the belief that this will help promote a return to eating.
At University Hospitals of Leicester NHS Trust it is
observed practice that 15 to 20% of patients require ‘res-
cue’ JEJ feeds to be re-instigated post-discharge due to
failing nutrition. This can require readmission to hos-
pital. The prevalence of home JEJ feeding after esopha-
gogastric cancer surgery has been reported at between
15 and 48% in published studies that have employed home
JEJ feeding [9-11]. It is unclear whether the practice of
feeding all patients by JEJ at home would be beneficial.
Studies that report medium-term endpoints are lacking
and are required to provide evidence of the benefits of ad-
junctive nutrition support in this patient group
Few studies have assessed the potential benefits of
continuing supplementary JEJ feeds after hospital dis-
charge [12]. In an institutional review of practice [13]
comparing the historical practice of not providing home
enteral support with the recent practice of home jeju-
nostomy feeding, home enteral support was associated
with better weight maintenance. The effect of enteral
nutrition on other outcome measures such as quality of
life is not known.
Following esophagectomy or total gastrectomy pa-
tients often struggle to establish an adequate nutritional
intake orally due to a combination of poor appetite, a
fear of eating, early satiety, abnormal gut transit, gastro-
intestinal symptoms such as nausea, reflux, and altered
bowel habits.
Studies have shown that over 60% of patients have an in-
adequate oral intake at time of hospital discharge, consum-
ing 70 and 65% of their energy and protein requirements
respectively [14]. An earlier study evaluating patients sixmonths after esophagectomy demonstrated that 64% of pa-
tients reported a loss of greater than 10% of their baseline
body mass index [15]. Estimates of the time taken to estab-
lish what would be considered a socially acceptable diet
after surgery are around six months [16].
Weight loss and poor nutritional intake may contrib-
ute to the detrimental effect on overall quality of life
(QoL) reported in these patients [17]. Although in general,
tumor location and stage of disease are the major determi-
nants of QoL, in esophageal cancer patient nutritional fac-
tors (dietary intake and weight loss) have been shown to
be as important in determining functional QoL scores
[18]. Global quality of life scores have been correlated with
both postoperative BMI and weight loss [19].
Little is known about the patient experience of home
tube feeding and studies often focus on heterogeneous
populations of variable age and dependency [20]. In eso-
phagogastric patients, the JEJ tube already remains in
place but any additional effect of using it is not known.
The effect on family and carers and their relationship to
the patient must also be considered as home tube fed
subjects are often reliant on support, and carers perceive
QoL very differently to that of the patient [21,22]. This
may increase the burden of treatment.
The aim of the current study is to pilot an investiga-
tion of the impact of six weeks of home JEJ feeding in
patients undergoing esophagectomy or total gastrectomy
for cancer and assess the feasibility of conducting an ap-
propriately powered multi-centre trial to evaluate the ef-
fectiveness of six weeks of home JEJ feeding. Specifically
this study will: (1) estimate participant recruitment and
retention rates in order to inform a larger multi-centre
trial, (2) estimate variability in disease-specific and gen-
eral QoL measures, (3) explore the relationship between
disease-specific and general QoL measures, (4) explore
the effect of home feeding on nutritional parameters and
total and/or oral intake, (5) estimate hospital readmission
rates, (6) explore participants’ and their carers' experiences
of living with a jejunostomy tube in situ and that of home
tube feeding, (7) test the feasibility of estimating health-
care costs, (8) provide preliminary evaluation of the cost-
effectiveness of postoperative home jejunostomy tube
feeding compared with standard care from an NHS and
personal social service.
Methods/Design
Study design and setting
This is a pilot prospective two-arm mixed-method ran-
domized controlled trial (RCT), with treatment-as-usual
as the control. Given the nature of the intervention and
control it is not possible to blind participants or those re-
sponsible for patient care. To minimize bias the research
dietitian who will collect study data will have no involve-
ment in patient care. This study will be conducted at a
Bowrey et al. Trials 2014, 15:187 Page 3 of 9
http://www.trialsjournal.com/content/15/1/187single site, University Hospitals of Leicester NHS Trust,
which draws patients from Leicester, Leicestershire and
Northamptonshire.
Trial management group
A trial management group has been setup including the
investigators, representatives from the Leicester Clinical
Trials Unit, and two former patients (one with their part-
ner). This group will meet every six months for the dur-
ation of the study to review study progress.
Participants
This study will recruit adult patients referred to the Uni-
versity Hospitals of Leicester NHS Trust Esophagogastric
Cancer Service with a confirmed diagnosis of esophago-
gastric cancer, deemed suitable for an esophagectomy or
total gastrectomy. The inclusion criteria are adults over 18
years of age with a confirmed diagnosis of esophagogastric
cancer who are undergoing a planned curative surgical
treatment esophagectomy (Ivor Lewis, three stage, or
transhiatal resection) or total gastrectomy with placement
of jejunostomy feeding tube. Patients will provide written
informed consent for participation in the study.
The exclusion criteria include an inability to provide
informed written consent, patients in whom artificial nu-
trition support at home is deemed inappropriate by ei-
ther the patient or healthcare team (due to safety issues
or home circumstances) and patients undergoing sub-
total gastrectomy (would not usually have jejunostomy
tube fitted).
Participation in this study does not exclude participa-
tion in national trials of perioperative chemotherapy.
Due to the different scheduling arrangements the two
treatment interventions (chemotherapy and jejunostomy
feeding) would not be administered concurrently. The
time frame for the administration of preoperative chemo-
therapy is prior to the planned six week jejunostomy feed-
ing period, and the time frame for the administration of
postoperative chemotherapy is after completion of the
planned six week jejunostomy feeding. Some participants
and their carer or partner will also participate in the quali-
tative study, for which the only additional criterion is a
willingness to participate.
Recruitment
Potential participants will be identified at the weekly
multidisciplinary, upper gastrointestinal cancer meetings
by a team member involved in the patient’s care. At the
surgical clinic potential participants will asked by a mem-
ber of the healthcare team whether they are happy to re-
ceive information about the study. If they agree they will
be provided with a participant information leaflet either
by a member of the research team (if available) or the clin-
ical team, and asked to give their consent for a member ofthe research team to contact them by telephone. A mini-
mum of 24 hours later a member of the research team will
contact the potential participant by telephone. If they
agree to take part they will be visited in hospital at their
pre-assessment clinic appointment. Those patients who
do not wish to be contacted by telephone can inform their
clinician that they wish to take part or telephone the re-
search team.
Potential participants for the qualitative exploratory
study will be those recruited into the RCT and their
carers. At the initial recruitment stage participants will
be asked to indicate on the consent form if they agree to
be interviewed. Following the six-week intervention
period, potential participants will be contacted and in-
vited to be interviewed. Where a partner or main carer
is identified, they too will be asked if they are interested
in participating. On agreement, a volunteer information
sheet will be posted out and consent will be taken prior
to the interview taking place. It is envisaged that includ-
ing the partner or carer will add to the depth of informa-
tion, particularly regarding experiences of home tube
feeding. The sample will also include male and female
patients without family or support at home. Participants
will be given the option to be visited at home or to at-
tend the hospital for interview. Recruitment to the study
will be conducted over a 20-month-period and individ-
ual participation in the study will last for 7 months.
Sample size
Home JEJ feeding is not routinely carried out at present
and there is no published data on the variables of inter-
est in this patient population. Consequently the sample
size in this pilot study was chosen to enable a sensible
estimation of the quantities of interest, in particular vari-
ability, whilst not exposing too large a number of partici-
pants to the full range of experimental procedures.
We therefore aim to recruit 60 subjects, 30 randomized
to home JEJ and 30 to treatment-as-usual, which (allowing
for up to 17% early withdrawal) would result in 50 partici-
pants completing the 6-week intervention period.
Randomization
Participants are randomized to either the control or
intervention group at enrolment, and prior to surgery,
so that baseline QoL and nutritional parameters can be
collected. We anticipate an early withdrawal rate due to
perioperative mortality or morbidity of around 5% based
on local experience. At the time of the operation it may
not be clinically suitable to place a JEJ tube in all sub-
jects, or some will not have a functioning JEJ tube (ap-
proximately 2%, due to kinking or blockage).
The randomized schedule is managed by the University
of Leicester Clinical Trials Unit, using computer generated
random assignment, using permuted block randomization,
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gastrectomy). A member of the research team (dietitian or
lead clinician) will randomize the participant through an
electronic Interactive Web Response System (IWRS). Par-
ticipants are sequentially assigned to groups as they are
entered into the study and the IWRS will provide a trial
participation number.
Neither the study participants nor the research team
are blinded to the allocation group. However the re-
search dietician has no role in determining clinical care
unless there are patient safety concerns. The research
team did not consider it either ethical or practical to ad-
minister placebo feed to the control group.Standard postoperative care
All participants will receive standard postoperative care
whilst in hospital, consisting of feeds via a JEJ tube placed
at the time of surgery. Tube insertion, commencement of
feeds, and subsequent increase in volume will follow nor-
mal clinical care (Figure 1).
Continuous JEJ feeds will be reduced to supplementary
overnight feeds (10 to 15 hours duration) when oral intake
starts (at approximately postoperative day 7) and continue
until the morning of the day of hospital discharge in all
participants. Dietary advice, including food fortificationRandomisatio
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Participants will be referred to the Home Enteral Nutri-
tion Service (HEN) and they will be taught (with or with-
out family support) to independently manage the JEJ feed
at home. For the first six weeks after discharge from hos-
pital, the participant and/or carer will be trained to admin-
ister overnight jejunostomy feeds via an electronic feeding
pump. The timings of feeds will be decided in conjunction
with the participant’s normal and expected routine follow-
ing discharge home. The participant’s individual nutri-
tional requirements will be assessed using prediction
equations [23,24] aiming to provide at least 50% of energy
and protein needs via the JEJ feed. The final amount pro-
vided for each subject will be adjusted depending on the
oral intake and weight change as assessed by the Home
Enteral Nutrition Service Dietitian (HEN).
Post-discharge dietetic follow-up will involve a routine
telephone call and home visit from HENs within the first
week of discharge and additional HEN input will be dic-
tated by nutritional need but will include at least one
further contact within the six-week intervention period.n.
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JEJ feed the participant receives to effectively manage
complications (gastrointestinal intolerance). The initial
adjustments will be to reduce the feed rate by 10 – 25
ml/hr, keeping the total volume of feed delivered the
same, but infused over a longer period (for example 100
ml/hr over 10 hours reduced to 80 ml/hr over 12.5
hours. The second step will be to adjust the feed com-
position (e.g. if the participant is experiencing an alter-
ation in bowel habit, fibre will either be reduced or
increased depending on the content of the current feed).
If these steps do not effect an improvement, the total
amount of energy provided by the feed will be reduced
(temporarily). JEJ feeds will only be stopped completely
after discussion with the Healthcare Team.
Control
Participants randomized to the control group will con-
tinue to receive routine clinical care: JEJ feeds will be dis-
continued on day of discharge, the JEJ tube will remain in
place until outpatient review in week six, and prior to dis-
charge the participants will be taught how to flush the JEJ
tube daily. Post-discharge dietetic follow-up will involve a
routine telephone call and home visit from HENs within
the first week of discharge. Additional HEN input will be
dictated by nutritional need but will include at least one
further contact within the six-week study period.
Following standard practice it may be considered ne-
cessary by the healthcare team to re-commence JEJ feeds
which we anticipate may be the case in up to 15% of the
control group. The criteria for recommencement of the
feed will include the following: (1) more than 5% weight
loss from baseline or hospital discharge value (visits 1 or
2), (2) clinical assessment by the managing team based
on functional status (worsening dysphagia, exhaustion,
or anorexia), or (3) oral energy intake reduced to one
third of the estimated requirements.
In these situations, JEJ feeds will be restarted accord-
ing to current practice (if necessary the patient will be
readmitted to hospital). The trial participant will con-
tinue to be monitored following the trial schedule and
the results will be analyzed on both an intention-to-treat
and perprotocol basis. The only difference between the
intervention and control arms will be the management
and administration of the supplementary JEJ feeding for
six weeks. All participants will receive clinical reviews
following routine care from the multi-disciplinary team
(MDT). It is likely that a small number of patients ran-
domized to either group will require home jejunostomy
feeding as part of their routine clinical care. These pa-
tients will continue feeding in accordance with their
planned care. Consideration will be given to withdrawing
the participant from the study where there has been
major protocol deviation.Qualitative protocol
For those participants recruited into the qualitative ex-
ploratory study, face-to-face semi-structured interviews,
will be conducted. The aim of this part of the study is to
explore the experiences of people with upper gastrointes-
tinal cancer and their carers regarding home jejunostomy
feeding. Initially, purposive sampling will be adopted to
ensure an appropriate selection of cases. The interviews
will all follow the same semi-structured format which
encourages exploration and discussion of the following
areas: experiences of home enteral feeding, ability to
comply with the feeding regimen, ability to care for the
JEJ tube, impact on activities of daily living, experiences
of eating and concerns over oral intake and nutritional
status.
This part of the study requires recruitment of a max-
imum of 20 participants and their carers or partners.
Outcome measures
Quantitative data
The primary outcome measures in this pilot study have
been chosen to determine whether or not an appropriately
powered definitive trial will be possible. To this effect, the
primary outcome measures are recruitment and retention
rates at six weeks and six months post-baseline. Additional
measures to be recorded at discharge, six weeks, three
months and six months after baseline focus on the nutri-
tional status and quality of life, specifically (1) nutritional
parameters of weight, body mass index, upper arm anthro-
pometry, and grip strength, (2) nutritional intake to include
total energy (kcal/d) and protein intake (g/day), contri-
bution of oral intake (food, fluids), oral nutritional sup-
plements, and JEJ feed, (3) postoperative complications,
(4) QoL using the European Organization for Research
and Treatment of Cancer (EORTC) generic cancer ques-
tionnaire (QLQ-C30)[25] and the EORTC disease specific
(esophagogastric) questionnaire (QLQ-OG25) [26].
To enable preliminary assessment of cost-effectiveness,
QoL using the five domain EuroQol health outcome in-
strument (EQ-5D) [27] will be measured at three and
six-months post-baseline and healthcare costs will be re-
corded for the duration of the study period. Survival data
will also be collected at 12-months post-surgery.
Adverse events and serious adverse events will be de-
fined in accordance with both the Medicines for Human
Use (Clinical Trials) Regulations 2004 (SI2004/1031) and
the subsequent amendment regulations (SI2006/1938) and
ICH-GCP. Expected adverse events associated with the
jejunostomy tube are blockage of the tube or inadvertent
removal of the tube rendering feeding impossible and skin
infection around the tube. Expected adverse events associ-
ated with the feed are bloating and diarrhoea.
Due to the nature of the surgery, it is anticipated that
up to 50% of the trial participants will experience a
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(after randomization, but before any trial treatment has
been administered). These adverse events will be re-
corded for scientific rigor but will not be reportable to
the study sponsor. These include death, return to the
operating theatre, return to the intensive care unit for
re-ventilation, prolonged ventilation (over 72-hours dur-
ation) and pneumonia. Table 1 details the planned visit
schedule, including acceptability in the timing of visits
and measurements. Assessments will either be carried
out at the hospital to coincide with routine clinic visits
or at home, depending on participant preference.
The University of Leicester Clinical Trials Unit has de-
veloped a trial-specific database. Data will initially be col-
lected onto paper case reports forms and subsequently
entered into the electronic database.Qualitative data
For those participants also recruited into the qualitative
part of the study there will be one interview to take place
at the end of the six-week intervention period. Interviews
will be conducted in a private room with a member of theTable 1 Summary of visit schedule and assessed parameters a
Parameters Assessed: Time Line
Pod = post operative day VISIT 1 VISIT 2
Week 1 WeEnrolment
(POD -2 wks)
Discharge
from hospital
(approx POD10)
Acceptable Variability +/- 7 days +/- 4 days
Int
Baseline Characteristics X
Weight (kg) X X
Height (m) X
Body mass index (kg / m2) X X
Anthropometrics X X
Mid arm circumference
Anthropometrics X X
TricepSkinfold
Thickness
Anthropometrics X X
Grip strength
Nutritional intake
(3 day food diary)
X
Post-operative complications X
Collected by
Healthcare Resource use X
Quality of Life EORTC X X
Quality of Life EQ-5D X
Semi-structured interviewresearch team who has received communication skills and
interview training. Interviews should take between 30 and
60 minutes. Following each interview the researcher will
make field notes including any observations. This will help
to inform reflexive reflection. The interview will be digit-
ally recorded and then transcribed verbatim. Participants
will be assigned a false name when the interview is tran-
scribed and the recording will be destroyed when no lon-
ger needed for study purposes. To help inform the design
of future research in this area, all participants will be
asked to provide details of their experiences of being in-
volved in a research trial, in particular the recruitment,
randomization, and assessment processes. All participants
will be asked on the consent form whether they consent
to being contacted at the end of their involvement in the
study to complete the questionnaire.Data analysis
Quantitative data
As this is a pilot study and we aim to estimate a number
of quantities necessary for the design and delivery of a de-
finitive multi-centre trial, the estimates calculated will bet each time point
ek 2 Week 3 Week 4 Week 5
VISIT 3 VISIT 4 VISIT 5
Week 6 3/12 Clinic 6 / 12 Clinic
+/- 7 days +/- 14 days
ervention period – home feeding
X X X
X X X
X X X
X X X
X X X
X X X
Research/Community Dietitian Prospectively
X X
X
X X X
X X
End of intervention period
Sample of up to 20 trial participants
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propriate. The proportion of eligible patients who consent
to participate in the pilot will be calculated, along with the
proportions in each intervention group completing six
weeks and six months of assessments. Hospital readmis-
sion rates will be presented by intervention group. Vari-
ability of the QoL measures will be calculated, both by
each group and pooled across both groups.
As it is anticipated that the likely outcome measure for
the multi-centre trial will be QoL, a comparison of the
QoL measure EORTC QLQ-C30 will be conducted using
the Students t-test to compare the mean between the
groups to provide a preliminary estimate of the treatment
effect. Distribution of the data will be assessed graphically
and if the normality assumption is considered to be unrea-
sonable a non-parametric approach will be taken. A sec-
ondary analysis, using analysis of covariance (ANCOVA)
and regression models will be conducted to adjust for type
of surgery (used as a stratification factor in randomization)
and baseline value of EORTC QLQ-C30.
The findings of the qualitative research may lead to a
different outcome measure being proposed as the pri-
mary in the definitive trial and consequently the other
QOL measures and other continuous outcomes at six
weeks, three months, and six months will be analyzed
similarly.
Qualitative data
A constant comparative approach to the analysis, using
the principles of grounded theory [27,28], will be per-
formed on the data. Data analysis will commence follow-
ing the first two interviews. Following this, in line with
the principles of grounded theory and to help focus the
data collection, theoretical sampling techniques will be
employed and the interview schedule amended as neces-
sary. Data collection will continue until saturation is
reached (no new themes are emerging). Similarities or
differences between each participant’s experience with
regards to a particular topic will be highlighted in the
data. Open coding followed by focused coding and the-
oretical memo writing will lead to the emergence of a
coding framework and ultimately theory development.
Data organization and retrieval will be managed using the
qualitative software package NVivo, QSR International
Ltd, Warrington, UK. Use of the software will also assist
with methodological auditability.
Health economics
An economic evaluation will be undertaken comparing
the two groups to determine the cost-effectiveness of JEJ
feeding. Patient questionnaires will be distributed to col-
lect the cost to the NHS or personal social service and
patient or carer cost. The main outcome for the cost util-
ity analysis will be Quality Adjusted Life Years (QALYs)calculated from EQ-5D-3 L using linear interpolation and
area under the curve methods. We will test the differences
in QALYs calculated from EQ-5D values and EORTC
QLQ-C30 measure of quality of life using the method de-
scribed by McKenzie and van der Pol [29]. Results will be
presented as incremental cost-effectiveness ratio (ICER)
between the two groups.
Ethics and dissemination
Approval for the study was granted by the Nottingham
Research Ethics Committee (protocol #11/EM/0383) in
January 2012 and recruitment commenced in July 2012.
The findings will be pertinent to the disciplines of both
dietetics and surgery. It is anticipated that the findings
will be presented at national meetings such as the British
Association of Parenteral and Enteral Nutrition (BAPEN),
the Association of Surgeons of Great Britain and Ireland,
and international meetings such as the American Gastro-
enterological Association and the Society for Surgery of
the Alimentary Tract. The study findings will be reported
in peer reviewed journals of interest to both dietetic and
surgical audiences.
We will publish a report of the research findings on
both the University of Leicester and the University Hos-
pitals of Leicester NHS Trust websites. We will produce
a ‘patient-friendly’ report, produced in close collabor-
ation with the lay members of the steering group. The
steering group will be central to the dissemination of re-
sults to the wider research community and other users
of the health service. It is expected that the Esophageal
Patients Association will be involved in the dissemination
of the research. We will present the results at the biannual
East Midlands Cancer Network meeting and the regional
BAPEN meetings. Service users will be informed at local
patient support groups and we will also aim to publish
results in the national patient support group (PINNT)
newsletter.
Discussion
Currently, there are no guidelines relating to the provision
of home feeding after esophagogastric cancer surgery. Pol-
icy is determined at a local level with wide heterogeneity
in UK practice. This pilot study is an essential precursor
for the development of an appropriately powered multi-
centre trial and will enable estimates of variability, recruit-
ment and retention rates, and treatment costs, as well as
inform choice of appropriate primary outcome for a
multi-centre trial. Importantly it will also allow the accept-
ability of home JEJ to patients to be ascertained. By pro-
viding home feeding it is envisaged that more patient care
would be delivered locally with a reduced need for hospital
readmission for nutritional problems in the first months
after surgery. This could represent a cost-effective use of
NHS resources. If demonstrated to be beneficial, the
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feeding would be applicable to the 1500 to 2000 patients
undergoing esophagectomy or total gastrectomy annu-
ally in the UK, potentially saving costs to the NHS and
improving the postoperative patient experience.
Trial status
The study has full ethical and institutional approval and
started recruitment in July 2012.
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